MarkMAwadMD

PubMed

• 1 citations
  Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer.
  Vaz, V., Biagio Ricciuti, Giuseppe Lamberti, Sreekar R Puchala, Navin R Mahadevan, Jia-Ren Lin, Joao V Alessi, Alexander Chowdhury, Yvonne Y Li, Xinan Wang, Liam Spurr...> ;Journal of Clinical Oncology. 2024 Apr 10
• Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
  Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee, Joao V Alessi, Adriana Barrichello, Victor R Vaz, Giuseppe Lamberti, Alessandro Di ...> ;Cancer Discovery. 2024 Apr 3
• Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
  Vallejo, J., Singh, H., Larkins, E., Drezner, N., Mishra-Kalyani, P., Tang, S., Beaver, J., Ricciuti, B., Awad, M.> ;The Oncologist. 2024 Feb 13
• 1 citations
  Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
  Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-P...> ;Nature Medicine. 2024 Mar 1
• Influence ofComutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in-Mutant Non-Small-Cell Lung Cancer.
  Naqash, A., Floudas, C., Aber, E., Maoz, A., Nassar, A., Adib, E., Choucair, K., Xiu, J., Baca, Y., Ricciuti, B., Alessi, J., Awad, M., Kim, C., Judd, J., Raez, L., Lo...> ;JCO Precision Oncology. 2024 Feb 1
• Association of Baseline Tumor-Specific Neoantigens and CD8T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors.
  Csaba Kerepesi, Hassan Mohammed Abushukair, Biagio Ricciuti, Amin H Nassar, Elio Adib, Joao V Alessi, Federica Pecci, Mehrdad Rakaee, Muhammad Zaki Hidayatullah Fadlul...> ;JCO Precision Oncology. 2024 Feb 1
• Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers.
  Cheong, T., Jang, A., Wang, Q., Leonardi, G., Ricciuti, B., Alessi, J., Federico, A., Lehtinen, M., Harris, M., Chiarle, R., Awad, M.> ;Research Square. 2024 Jan 17
• Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
  Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zar...> ;Nature Medicine. 2024 Mar 1
• 1 citations
  Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.
  Joao V Alessi, Adam Price, Allison L Richards, Biagio Ricciuti, Xinan Wang, Arielle Elkrief, Federica Pecci, Alessandro Di Federico, Malini M Gandhi, Emily S Lebow, Pa...> ;Journal for Immunotherapy of Cancer. 2023 Nov 1
• Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
  Hye Ryun Kim, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet K Cheema, Delvys Rodriguez-Abreu, Mirjana Wollner, James Chih-Hsin ...> ;JTO Clinical and Research Reports. 2023 Nov 1
• 4 citations
  Liquid biopsy epigenomic profiling for cancer subtyping.
  Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zar...> ;Nature Medicine. 2023 Nov 1
• 3 citations
  Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC.
  Vaz, V., Joao V Alessi, Xinan Wang, Arielle Elkrief, Biagio Ricciuti, Yvonne Y Li, Hersh Gupta, Liam F Spurr, Hira Rizvi, Jia Luo, Federica Pecci, Giuseppe Lamberti, G...> ;Journal of Thoracic Oncology. 2023 Nov 1
• 2 citations
  Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
  Mingrui Zhu, Jiwoong Kim, Qing Deng, Biagio Ricciuti, Joao V Alessi, Buse Eglenen-Polat, Matthew E Bender, Hai-Cheng Huang, Ryan R Kowash, Ileana Cuevas, Zachary T Ben...> ;Cancer Cell. 2023 Oct 9
• 2 citations
  Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
  Arielle Elkrief, Biagio Riccuiti, Joao V Alessi, Teng Fei, Hannah L Kalvin, Jacklynn V Egger, Hira Rizvi, Rohit Thummalapalli, Guiseppe Lamberti, Andrew Plodkowski, Ma...> ;The Oncologist. 2023 Nov 2
• 2 citations
  Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
  Jürgen Wolf, Pierre-Jean Souquet, Koichi Goto, Alexis Cortot, Christina Baik, Rebecca Heist, Tae Min Kim, Ji-Youn Han, Joel W Neal, Aaron S Mansfield, Isabelle Gillote...> ;Clinical Lung Cancer. 2023 Nov 1
• Letter to the Editor: Reply to Kus and Aktas.
  Joao V Alessi, Mark M Awad> ;Journal of Thoracic Oncology. 2023 Aug 1
• 4 citations
  Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC.
  Joao V Alessi, Biagio Ricciuti, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe Lamberti, Arielle Elkrief, Scott J Rodig, Emily S Lebow, Jordan E Eicholz,...> ;Nature Communications. 2023 Jul 15
• 3 citations
  Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
  Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, Daniel Muldoon, Hira Rizvi, Arielle Elkrief, Jia Luo, Joao V Alessi, Federica Pecci, Giuseppe Lamberti, Ale...> ;Clinical Cancer Research. 2023 Nov 1
• 7 citations
  ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer.
  Ines Mota, Enrico Patrucco, Cristina Mastini, Navin R Mahadevan, Tran C Thai, Elisa Bergaggio, Taek-Chin Cheong, Giulia Leonardi, Elif Karaca-Atabay, Marco Campisi, Te...> ;Nature Cancer. 2023 Jul 1
• 2 citations
  Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
  Vaz, V., Biagio Ricciuti, Arielle Elkrief, Joao Alessi, Xinan Wang, Yvonne Li, Hersh Gupta, Daniel M Muldoon, Arrien A Bertram, Federica Pecci, Giuseppe Lamberti, Ales...> ;Clinical Cancer Research. 2023 Jul 5
• 1 citations
  Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
  Arielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, Samantha Brown, Hira Rizvi, Isabel R Preeshagul, Xinan Wang, Federica Pecci, Alessandro Di Federico, Giuseppe L...> ;Journal for Immunotherapy of Cancer. 2023 Jul 1
• 12 citations
  Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC.
  Vaz, V., Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R Vaz, Giuseppe Lamberti, Rosa L Frias, Deepti Venkatraman, Claudia A ...> ;Journal of Thoracic Oncology. 2023 Jun 1
• Letter to the Editor: Reply to Zhao, Wu, and Ma.
  Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, Adam J Schoenfeld, Mark M Awad> ;Journal of Thoracic Oncology. 2023 Jun 1
• Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a P...
  Edward B Garon, Alexander I Spira, Sarah B Goldberg, Jamie E Chaft, Vassiliki Papadimitrakopoulou, Tina Cascone, Scott J Antonia, Julie R Brahmer, D Ross Camidge, John...> ;Journal of Thoracic Oncology. 2023 Aug 1
• 10 citations
  Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
  Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Gr...> ;Nature Genetics. 2023 May 1
• Join now to see all

Journal Articles

• Authors’ Response  
  Matthew P Cheng, Mark M Awad, Journal of Thoracic Oncology

Lectures

• Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKIs) in MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• ECHO-305/KEYNOTE-654: A phase 3, randomized, double-blind study of first-line epacadostat plus pembrolizumab vs pembrolizumab plus placebo for metastatic non small cel... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018